Logo Image
Opinion|Videos|August 27, 2026

Epcoritamab Plus R² in Community Practice: Expanding the Second-Line Landscape in RRFL

Tara Graff discussed her experience with epcoritamab-based combinations in follicular lymphoma, noting that her practice's participation in both epcoritamab monotherapy and combination therapy trials has provided her with firsthand familiarity with the regimen and that the efficacy data, particularly the overall response and complete response rates associated with epcoritamab plus R², is compelling.

Episodes in this series

In 'Epcoritamab Plus R² in Community Practice: Expanding the Second-Line Landscape in RRFL,' Tara Graff, DO, MS delves into the following critical question:

Epcoritamab plus lenalidomide and rituximab received a Category 1 recommendation in the latest NCCN guidelines. What has been your experience onboarding this therapy, and how does it compare to other second-line options available?

Tara Graff discussed her experience with epcoritamab-based combinations in follicular lymphoma, noting that her practice's participation in both epcoritamab monotherapy and combination therapy trials has provided her with firsthand familiarity with the regimen and that the efficacy data, particularly the overall response and complete response rates associated with epcoritamab plus R², is compelling. She addressed the primary concern that gives community oncologists pause when considering bispecific antibodies, cytokine release syndrome (CRS), and offered meaningful reassurance that the CRS rates observed with epcoritamab plus R² are substantially lower than those seen with epcoritamab monotherapy. Tara Graff emphasized that community oncologists who are already using bispecifics or are beginning to explore them will find epcoritamab plus R² a particularly accessible entry point given its favorable safety profile, and called on the field to prioritize education and awareness around this regimen so that the lag between approval and community adoption is shortened and more patients can benefit from its powerful efficacy.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'From Guidelines to Community Practice: Translating the Latest NCCN RRFL Updates Into Action,' features Tara Graff advancing her conversation on follicular lymphoma and focusing on the most important latest NCCN guideline updates in RRFL.

Related Content